Newsletter

Int. Rev. Allergol. Clin. Immunol. Family Med., 2016, XXII/4: 226-230 Maximize

Int. Rev. Allergol. Clin. Immunol. Family Med., 2016, XXII/4: 226-230

Title: Pathogenetic determination of biological medicines application in patients with bronchial asthma 

Authors: Majkut I, Płusa T. 

More details

05-04-2016

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Pathogenetic determination of biological medicines application in patients with bronchial asthma


Majkut I, Płusa T.

EMC Medical Institute SA – Department of Internal Medicine and Lung Disease, Hospital st. Anna in Piaseczno, Poland

Int Rev Allergol Clin Immunol Family Med, 2016; Vol. 22, No. 4, 226

Asthma is a heterogeneous, chronic disease that includes several different phenotypes, which are defined by clinical, functional and pathobiological features. Specification of each phenotypes leads to choosing more effective treatment. Biological drugs are focused to inflammatory cells, immunoglobulin E and cytokines. Omalizumab (anty-IgE) and mepolizumab (anty-IL-5) are used in severe eosinophilic asthma treatment in 4 and 5 stage of illness according to GINA 2016 guidelines. A lot of new monoclonal particles as tralocizumab,dupilumab and other are in preclinical trials.

Key words: eosinophilic asthma, asthma phenotypes, biological drugs, omalizumab, reslizumab